
    
      ET190L ARTEMISâ„¢ is a novel chimeric T-cell therapy platform that in preclinical studies,
      functionally matches the efficacy of CAR T cells, but dramatically reduces the release of
      cytokines upon killing of target-positive tumors.
    
  